Total Pageviews

Friday, January 13, 2017

Case Study and Case Report 2017; 7(1): 5 - 14.

Rama B, Lokaj AS. Multiple subconjunctival Bevacizumab injections for recurrent pterygium. Case Study and Case Report 2017; 7(1): 5 - 14. ABSTRACT FULL TEXT

ABSTRACT

A pterygium is defined as a triangular ocular surface lesion growing from conjunctiva
towards limbus cornea and corneal surface. It is also characterized as fibrovascular growth,
hyperplastic epithelial proliferation and tissue degeneration leading to persistent chronic
inflammation. It usually appears more frequently in patients who live in hot climate and
constant sun or ultraviolet exposure. Other risk factors are toxic material exposure, dry eye
and familiar predisposition. There are 4 types of pterygium basing on its extension on corneal
surface. Irritation and visual acuity problems are the most common symptoms in advanced
stages, but small lesions can be asymptomatic. Although the pathogenesis is not yet clearly
understood, it is considered as chronic cellular proliferation caused by transforming growth
factor, (TGF)-β1 known as one of the main mediators of fibroblast stimulation and vascular
endothelial growth factor, VEGF the main role factor mediator of angiogenesis and
fibroblast stimulation. In our study we represent a case series of patient treated with
subconjuctival Bevacizumab injections for ten weeks. Over expression of the vascular
endothelial growth factor (VEGF) associated with intense angiogenesis process shows that it
is an obvious factor which with significant role in pterygium development. There is possible
adjuvant therapy for pterygium treatment. Bevacizumab is anti-VEGF, a human monoclonal
antibody against VEGF with anti angiogenic effect which decreases fibrovascular invasion
and migration and decreases the fibroblast expression. It is used in ophthalmology as an offlabel
treatment for retinal disease and also pterygium treatment. We represent the
effectiveness of multiple Bevacisumab injections in pterygium. Based on our evaluation of
the case series with subconjuctival Bevacizumab injections without following surgery, we
came to the conclusion that there are no significant changes in recurrence of pterygium.

Keywords: Recurrent pterygium, suconjunctival bevacizumab

Thursday, January 12, 2017

Case Study and Case Report 2017; 7(1): 1 -4.

Fredon S. False non-reactive VDRL in a patient with later syphilis and underlying HIV infection: A case report. Case Study and Case Report 2016; 7(1): 1 -4.ABSTRACT  FULL TEXT

ABSTRACT

A pterygium is defined as a triangular ocular surface lesion growing from conjunctiva
towards limbus cornea and corneal surface. It is also characterized as fibrovascular growth,
hyperplastic epithelial proliferation and tissue degeneration leading to persistent chronic
inflammation. It usually appears more frequently in patients who live in hot climate and
constant sun or ultraviolet exposure. Other risk factors are toxic material exposure, dry eye
and familiar predisposition. There are 4 types of pterygium basing on its extension on corneal
surface. Irritation and visual acuity problems are the most common symptoms in advanced
stages, but small lesions can be asymptomatic. Although the pathogenesis is not yet clearly
understood, it is considered as chronic cellular proliferation caused by transforming growth
factor, (TGF)-β1 known as one of the main mediators of fibroblast stimulation and vascular
endothelial growth factor, VEGF the main role factor mediator of angiogenesis and
fibroblast stimulation. In our study we represent a case series of patient treated with
subconjuctival Bevacizumab injections for ten weeks. Over expression of the vascular
endothelial growth factor (VEGF) associated with intense angiogenesis process shows that it
is an obvious factor which with significant role in pterygium development. There is possible
adjuvant therapy for pterygium treatment. Bevacizumab is anti-VEGF, a human monoclonal
antibody against VEGF with anti angiogenic effect which decreases fibrovascular invasion
and migration and decreases the fibroblast expression. It is used in ophthalmology as an offlabel
treatment for retinal disease and also pterygium treatment. We represent the
effectiveness of multiple Bevacisumab injections in pterygium. Based on our evaluation of
the case series with subconjuctival Bevacizumab injections without following surgery, we
came to the conclusion that there are no significant changes in recurrence of pterygium.

Keywords: Recurrent pterygium, suconjunctival bevacizumab


Monday, January 9, 2017

NEW JOURNAL HOMEPAGE (case-study-case-report.simdif.com)

PLEASE VISIT OUR NEW WEBSITE FOR OUR JOURNAL
CASE STUDY AND CASE REPORT AT
http://case-study-case-report.simdif.com/CASE STUDY AND CASE REPORT